The South Korean health authority is seemingly giving a green light to an immunotherapy Tecentriq for its combination therapy as a first-line treatment in liver cancer.

A pharmaceutical industry source reported on Mar. 9 that the Health Insurance Review and Assessment Service (HIRA) Cancer Deliberation Committee approved of the clinical efficacy in Roche’s Tecentriq (atezolizumab) plus Avastin (bavacizumab) combination therapy for patients with unresectable hepatocellular carcinoma, who have not received prior systemic therapy. The first threshold for the reimbursement was passed at the committee meeting convened on Feb. 24.

The Tecentriq combination therapy has won the first-line trea